Free Trial
NASDAQ:TXMD

TherapeuticsMD Q1 2025 Earnings Report

TherapeuticsMD logo
$1.06 0.00 (0.00%)
Closing price 03:51 PM Eastern
Extended Trading
$1.06 0.00 (0.00%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TherapeuticsMD EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

TherapeuticsMD Revenue Results

Actual Revenue
$0.39 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TherapeuticsMD Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

TherapeuticsMD's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

TherapeuticsMD Earnings Headlines

TherapeuticsMD: Q2 Earnings Snapshot
A Huge Shift Is Underway in America
Wall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who predicted the 2008 crash and 2020 says today's soaring markets are NOT a bubble - they're something far stranger and more dangerous. He says it's about to change everything you know about money.tc pixel
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) (NASDAQ:TXMD) is a women's healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause. The company also markets BIJUVA, the first combination bio-identical estrogen and progesterone capsule for the treatment of moderate to severe hot flashes. In addition, TherapeuticsMD is advancing a pipeline of novel contraceptive technologies, including transdermal delivery systems and oral formulations aimed at providing more flexible dosing options.

Founded in 2015 and headquartered in Boca Raton, Florida, TherapeuticsMD has built a leadership team with extensive experience in women’s health and specialty pharmaceuticals. The organization emphasizes strategic partnerships and targeted clinical development to support product launches and lifecycle management. With a commitment to research and patient-centric care, TherapeuticsMD continues to expand its portfolio and strengthen its position in the women’s health market.

View TherapeuticsMD Profile

More Earnings Resources from MarketBeat